You have 9 free searches left this month | for more free features.

JAK2 kinase inhibitor

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting
  • Abatacept
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial People's Hospital
Jul 5, 2022

Myelomonocytic Leukemia Trial in United States (Ruxolitinib)

Completed
  • Myelomonocytic Leukemia
  • Tampa, Florida
  • +5 more
Sep 9, 2022

Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

Recruiting
  • Alopecia Areata
  • Janus Kinase 1 and 2
  • Sohag, Egypt
    Sohag University hospitals
May 12, 2023

Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

Completed
  • Myelofibrosis
  • Imetelstat 4.7 mg/kg
  • Imetelstat 9.4 mg/kg
  • Birmingham, Alabama
  • +71 more
Aug 17, 2021

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)

Not yet recruiting
  • Myelofibrosis
  • Moderate Thrombocytopenia
  • (no location specified)
Jul 31, 2023

Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

Not yet recruiting
  • Preterm Labor
    • (no location specified)
    May 9, 2023

    Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

    Not yet recruiting
    • Diabetes Mellitus, Type 1
    • Abrocitinib 200 MG Oral Tablet
    • +2 more
    • (no location specified)
    Feb 21, 2023

    Breast Cancer Trial in Guangzhou (Take probiotics)

    Recruiting
    • Breast Cancer
    • Take probiotics
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Mar 6, 2023

    Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)

    Active, not recruiting
    • Chronic Graft vs Host Disease
    • Chronic Graft-Versus-Host Disease
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Nov 29, 2022

    BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

    Recruiting
    • BCR-JAK2 Fusion Protein Expression
    • +11 more
    • Palo Alto, California
    • +3 more
    Oct 5, 2022

    Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

    Completed
    • Gastrointestinal Stromal Tumors (GISTs)
    • Imatinib Mesylate
    • Seoul, Korea, Republic of
      Asan Medical Center
    Dec 30, 2022

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

    Recruiting
    • Acute Myeloid Leukemia
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 18, 2022

    Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

    Active, not recruiting
    • Multiple Sclerosis
    • tolebrutinib 60mg
    • tolebrutinib 120mg
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)

    Recruiting
    • Idiopathic Inflammatory Myopathies
    • London, United Kingdom
      King's College Hospital NHS Foundation Trust
    May 19, 2022

    Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

    Recruiting
    • Chronic Hand Dermatitis
    • Rochester, New York
      UR Medicine Dermatology College Town
    Aug 9, 2022

    Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy Trial in Philadelphia (Netarsudil 0.02% Ophthalmic Solution

    Not yet recruiting
    • Rhegmatogenous Retinal Detachment
    • Proliferative Vitreoretinopathy
    • Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
    • Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
    • Philadelphia, Pennsylvania
      Wills Eye Physicians - Mid Atlantic Retina
    Dec 13, 2022

    Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)

    Active, not recruiting
    • Primary Myelofibrosis
    • Secondary Myelofibrosis
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +11 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 10, 2023

    CNS Lymphoma Trial in Petah Tikva (Imbruvica)

    Recruiting
    • Central Nervous System Lymphoma
    • Petah Tikva, Israel
      Hematology Institute
    May 9, 2022

    Alzheimer Trial in New York (MW150, Placebo)

    Not yet recruiting
    • Alzheimer Disease
    • New York, New York
      Columbia University Irving Medical Center
    Mar 13, 2022

    Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

    Active, not recruiting
    • Neoplasm
    • Beijing, China
    • +5 more
    Jan 31, 2023

    Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • Miami, Florida
      University of Miami
    Apr 12, 2023

    Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia Trial in Rochester (Biospecimen

    Recruiting
    • Recurrent Chronic Myelomonocytic Leukemia
    • Refractory Chronic Myelomonocytic Leukemia
    • Biospecimen Collection
    • +3 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023